Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1503168 | 0.90 | KMT2A (0.49) | KMT2AMAPTLIMK2LMNAALDH1A1 | |
| SCHEMBL1503080 | 0.89 | KMT2A (0.51) | KMT2AMAPTLIMK2LMNAALDH1A1 | |
| SCHEMBL1503101 | 0.88 | KMT2A (0.49) | KMT2AMAPTLIMK2LMNAALDH1A1 | |
| SCHEMBL1503161 | 0.82 | KMT2A (0.49) | KMT2AMAPTLIMK2LMNAALDH1A1 | |
| SCHEMBL2219295 | 0.75 | HDAC6 (0.42) | KMT2AMAPTL3MBTL1 | |
| SCHEMBL1503139 | 0.73 | LMNA (0.60) | KMT2AMAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL2186250 | 0.73 | LMNA (0.60) | KMT2AMAPTLMNAALDH1A1L3MBTL1 | |
| SCHEMBL1503166 | 0.71 | POLB (0.50) | MAPTLMNAALDH1A1L3MBTL1HPGD | |
| SCHEMBL8775174 | 0.70 | KMT2A (0.61) | KMT2AMAPTALDH1A1HPGDMEN1 | |
| SCHEMBL19755568 | 0.69 | LMNA (0.53) | MAPTLMNAALDH1A1MMP2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | claimed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | claimed |
| US-8742123-B2 | HIV integrase inhibitors from pyridoxine | TAIMED BIOLOGICS, INC. (TW) | 2014-06-03 | — | — | US | disclosed |
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | KMT2A 1953/4885MAPT 2577/4885LIMK2 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.